Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to test the safety and feasibility of autologous mesenchymal stem cell therapy in HLA-DR mismatched patients with subclinical rejection and or an increase in IF?TA in the renal biopsy 4 weeks or 6 months after renal transplantation.


Clinical Trial Description

Kidney transplantation has improved survival and quality of life for patients with end-stage organ failure. Despite dramatic improvements in short-term survival, long-term survival of renal allografts has changed little during the past decade. Recently, it has been demonstrated that chronic lesions originate already very early after transplantation and that subclinical rejection (SCR) in protocol biopsies is a risk factor for late graft loss. However the efficacy of high-dose corticosteroids and other therapies for the treatment of SCR have been shown to be inadequate. Thus, despite the availability of a range of available medications there remains a need for therapeutic alternatives because patients may not respond to existing therapeutic choices, they do not show an improvement of the fibrosis reaction or an effect on long term survival, or they may develop immunosuppression induced serious (sometimes fatal) side effects and toxicities.

In recent years it has become evident that bone marrow (BM) derived mesenchymal stem cells have potent immunomodulatory effects. MSCs are pluripotent cells that can differentiate into several mesenchymal tissues, including fibroblasts, osteoblasts, adipocytes and chondrocyte progenitors. MSCs have potent immunosuppressive effects on T and B cells in vitro and in animal models of chronic inflammation. Encouraging results have been obtained in patients with steroid resistant acute and severe Graft versus Host Disease (GvHD). The investigators hypothesize that infusion of MSCs may similarly provide a novel treatment option in the treatment of patients with allograft rejection with less side effects than existing immunosuppressive therapies.This study will evaluate the safety and feasibility of MSC therapy in renal recipients.

In total 15 de novo renal recipients of 2 HLA-DR mismatched living donors, men and women, 18-65 years of age, will be recruited from the renal transplant clinics of the LUMC. Only patients with SCR abd or an increase in IF/TA in the protocol biopsy 4 weeks or 6 months after transplantation will receive MSC infusions. MSCs from patients without SCR in their biopsy will be only used for feasibility and function studies (as described earlier). Subjects will receive two doses of 1 x 10.6 MSCs per kilogram body weight, intravenously, 7 days apart. The investigators will investigate safety of MSC therapy by assessing the rate of (serious) adverse events in the study population using the World Health Organization (WHO) criteria. Feasibility will be obtained by determining the number of expanded MSCs in relation to the amount of BM collected, number of passages required and time to reach study target doses. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00734396
Study type Interventional
Source Leiden University Medical Center
Contact
Status Completed
Phase Phase 1/Phase 2
Start date February 2009
Completion date December 2012

See also
  Status Clinical Trial Phase
Recruiting NCT00987103 - Pharmacokinetic Study to Rectal and Sublingual Administration of Tacrolimus in Future Kidney Transplant Patients Phase 1
Completed NCT03699839 - Reducing the Burden of Influenza After Solid-Organ Transplantation Phase 2/Phase 3
Completed NCT01633424 - The "Stanford Integrated Psychosocial Assessment for Transplant" (SIPAT)
Completed NCT01254955 - Antibody Production Following H1N1 Influenza Vaccination in Organ Transplant Patients N/A
Completed NCT00948883 - Study of Cancers After Solid Organs Transplants N/A
Recruiting NCT02314949 - Leuven Tolerogenic Protocol for Intestinal Transplantation N/A
Recruiting NCT01283295 - Immune Monitoring and Assay Development in Organ Transplant Recipients
Not yet recruiting NCT03861962 - Re-evaluation of Donor-specific Anti-HLA Alloantibodies Immunoassay After Organ Transplantation, From Antigen Level to Epitope Level
Completed NCT01123187 - Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation N/A
Completed NCT00213304 - The Safety of Oka Varicella in Children Prior to Solid Organ Transplantation Phase 3
Completed NCT01515072 - Remote Ischemic Preconditioning in Neurological Death Organ Donors N/A
Completed NCT00904579 - Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease
Recruiting NCT04687865 - Constitution of a Biobank for Studies Related to Organ Transplantation (Lyon Centaure Biocollection)
Recruiting NCT00611494 - Gastrointestinal Tolerability of MMF vs EC-MPS in Maintenance Transplant Patients Treated With Calcineurin Inhibitors Phase 4
Completed NCT02852902 - Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to ESBL- or Carbapenemase-producing Enterobacterales in Solid Organ Transplantation: an Observational Multinational Study.
Completed NCT05685888 - Effect of Ursodeoxycholic Acid on Preventing Covid-19 Infection in Patients With Organ Transplantation
Recruiting NCT00792064 - Systematic Evaluation of Predictors of Quality of Life in the Long-term After Solid Organ Transplantation N/A
Completed NCT00286871 - Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen Phase 1
Recruiting NCT03997253 - Optimizing Long-term Survival in Organ Transplantation: From Physiopathology to Optimized Patient Management N/A
Recruiting NCT01256931 - Antibody Levels Against 2009 Influenza A H1N1 One Year After Vaccination With Pandemrix and 2010 Fluarix Booster in Organ Transplant Recipients. N/A